Previous 10 | Next 10 |
Orchard Therapeutics (NASDAQ: ORTX ) initiated with Overweight rating at Barclays. More news on: Orchard Therapeutics plc, Idera Pharmaceuticals, Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
The Trump administration has allocated $1.8B to help states and local governments tackle opioid addiction in their respective areas. The funds will be distributed through Substance Abuse and Mental Health Services and the CDC for treatment and data gathering. More news on: Teva Pharmaceu...
An Oklahoma district court has ordered Johnson & Johnson (NYSE: JNJ ) to pay $572M over its role in the opioid epidemic there. One-time co-defendants Purdue Pharma and Teva Pharmaceutical Industries (NYSE: TEVA ) settled earlier for $270M and $85M, respectively. More news on: John...
Endo International ( ENDP +18.4% ) is up on below-average volume in early trade on the heels of its announcement that subsidiaries Endo Pharmaceuticals, Endo Health Solutions, Par Pharmaceutical and Par Pharmaceutical Companies have agreed in principle to settle lawsuits brought by two c...
Drug distributors McKesson ( MCK -4.9% ), Cardinal Health ( CAH -5.4% ) and AmerisourceBergen ( ABC -4.7% ) are under pressure in apparent response to a Bloomberg repor t that they have proposed paying a total of $10B to settle all claims related their respective roles in the opioid e...
Alkermes ( ALKS ) is a mid-cap biopharmaceutical company focused on drug development for chronic central nervous system diseases, such as schizophrenia, major depressive disorder and multiple sclerosis. The company has two approved drugs, ARISTADA (aripiprazole lauroxil) for the treatment of...
Alkermes plc ( ALKS +5.4% ) is up on average volume in reaction to positive topline data from a Phase 3 clinical trial, EVOLVE-MS-2 , evaluating the GI tolerability of diroximel fumarate (ALKS 8700/BIIB098) compared to Biogen's ( BIIB +1.1% ) TECFIDERA (dimethyl fumarate) in patients ...
— Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study’s Primary Endpoint Assessing Self-Reported GI Events — — Discontinuations Due to GI Events were Less than 1% for Diroximel Fumarate —...
Alkermes plc ( ALKS +2.9% ) inks an agreement with Amneal Pharmaceuticals LLC ( AMRX +1.6% ) settling the latter's challenge to a U.S. patent covering opioid/alcohol dependence med VIVITROL (naltrexone for extended-release injectable suspension) that expires in 2029. More news on: Al...
DUBLIN , July 29, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it has entered into a settlement and license agreement (the agreement) with Amneal Pharmaceuticals LLC (Amneal) to resolve Amneal's inter partes review (IPR) petition challenging U.S. Pat...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.76%Change Percent:
Alkermes plc Company Name:
ALKS Stock Symbol:
NASDAQ Market:
Alkermes plc Website:
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...